Perseus Proteomics Inc. (TYO:4882)

Market Cap	2.33B -59.9%
Revenue (ttm)	135.00M +12.5%
Net Income	-718.00M
EPS	-48.17
Shares Out	15.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	363,000
Open	162.00
Previous Close	161.00
Day's Range	153.00 - 162.00
52-Week Range	154.00 - 478.00
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	May 14, 2026

About Perseus Proteomics

Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell;...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2001
• Employees: 32
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4882

Financial Performance

In fiscal year 2026, Perseus Proteomics's revenue was 135.00 million, an increase of 12.50% compared to the previous year's 120.00 million. Losses were -718.00 million, -20.58% less than in 2025.